Cargando…
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
BACKGROUND: There is limited evidence to support the efficacy of current pharmaceutical agents in reducing the risk of hip fracture in older postmenopausal women with established osteoporosis. OBJECTIVE: To clarify the efficacy of risedronate in reducing the risk of hip fracture in elderly postmenop...
Autores principales: | Masud, Tahir, McClung, Michael, Geusens, Piet |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785868/ https://www.ncbi.nlm.nih.gov/pubmed/19966913 |
Ejemplares similares
-
Risedronate’s Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis
por: Gates, Brian J., et al.
Publicado: (2012) -
Effects of risedronate on fracture risk in postmenopausal women with osteopenia
por: Siris, E. S., et al.
Publicado: (2007) -
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
por: McClung, M. R., et al.
Publicado: (2012) -
Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women
por: Osaki, M., et al.
Publicado: (2011) -
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA
por: Eisman, John A., et al.
Publicado: (2023)